THE 30-SECOND OVERVIEW
At a glance
Sermorelin and MK-677 sit on opposite sides of the system that controls growth hormone. Sermorelin is the hormone the hypothalamus itself uses to ask for growth hormone, trimmed to its active fragment. MK-677 imitates ghrelin, a stomach hormone that reaches the same pituitary cells by a second receptor. Both raise growth hormone. They do it from different doors, at different speeds, and with evidence records that were built for different purposes.
What each one is
Sermorelin is GHRH(1-29), the first 29 amino acids of human growth hormone-releasing hormone, synthesised as the acetate salt and otherwise unmodified. Its full activity lives in those 29 residues, and it binds the GHRH receptor on pituitary somatotrophs exactly as the native 44-residue hormone does. It held FDA approval as Geref for diagnostic use and for paediatric growth hormone deficiency before being withdrawn from the market in 2008 for commercial reasons (Prakash and Goa, 1999), a history covered in Tesamorelin vs Sermorelin.
MK-677, or ibutamoren, is a spiroindoline small molecule and an agonist at GHS-R1a, the ghrelin receptor. It is not a peptide, it survives oral administration, and it was developed by Merck precisely as an orally active alternative to injected secretagogues (Ghigo et al., 1998). It is stocked as a 25mg per mL oral liquid and as 15mg tablets.
Two receptors, one pituitary
The GHRH receptor and the ghrelin receptor are not redundant. Fuh and colleagues (1998) described the secretagogue class as functional somatostatin antagonists that potentiate the action of GHRH, and Ghigo's review of the same year recorded that the growth hormone response to a secretagogue is synergistic with GHRH. That is the stated rationale behind protocols that pair a GHRH-receptor agonist with a ghrelin-receptor agonist: they are two inputs to the same release, not two copies of one input.
It also explains the different signal shapes. Sermorelin's native sequence is cleaved by dipeptidyl peptidase-4 within minutes, so a dose produces a single sharp growth hormone pulse that mirrors an endogenous GHRH burst, which is exactly what made it useful as a diagnostic probe of pituitary function. MK-677, taken once a day, raised 24-hour growth hormone by amplifying the pulses that were already occurring, taller and with higher troughs but no more numerous (Chapman et al., 1996), and Copinschi (1996) found that bedtime doses increased pulse frequency through additional low-amplitude pulses. One compound adds a pulse; the other lifts the whole rhythm.
The evidence records
Sermorelin's record is a regulatory one. It was studied and approved for stimulating growth hormone as a diagnostic test and for treating growth hormone deficiency in children, with published clinical use in that setting reviewed by Prakash and Goa (1999). Its record in adults for any other purpose is thin, and its market withdrawal was not a safety action.
MK-677's record is a research one, and it is long. Chapman (1996) dose-ranged 2, 10 and 25mg in adults aged 64 to 81 and found 25mg restored IGF-1 to young-adult levels. Svensson (1998) ran 25mg daily for eight weeks in obese men and measured a 40 percent IGF-1 rise with an increase in fat-free mass. Nass (2008) ran 25mg daily for two years in 65 healthy older adults: fat-free mass rose, visceral fat did not fall, fasting glucose rose, insulin sensitivity fell, and strength and function did not change. Trials in hip fracture, Alzheimer's disease and haemodialysis raised IGF-1 reliably without moving their clinical endpoints, and the 2010 hip-fracture study was stopped early over a heart-failure signal. The full record is in our MK-677 dosage research article.
The difference in kind matters more than the difference in size. Sermorelin's data answer a diagnostic and paediatric question. MK-677's data answer a physiological one, what sustained oral ghrelin-receptor agonism does to growth hormone, IGF-1, body composition and metabolism in adults, and they include enough negative results to be believed.
Route and handling
Sermorelin is a lyophilised peptide that needs reconstitution, cold storage and injection, and its minutes-long half-life means the timing of each administration is the whole protocol.
MK-677 is stable in solution and in tablet form, is administered orally, and was given once daily, usually at bedtime, in every published trial. For a programme that reproduces a published quantity, the liquid at 25mg per mL puts the trial figure at 1.0mL and the tablets at 15mg each; these are concentration calculations, not recommendations.
Where each one fits
Sermorelin belongs in work on GHRH-receptor signalling, on pituitary responsiveness, and on the physiology of a single native pulse. MK-677 belongs in work on oral delivery, on sustained IGF-1 elevation, and on the metabolic trade-offs that come with it. A study that wants both receptors engaged at once is asking the synergy question, which is the same question the CJC-1295 with ipamorelin blend exists for on the peptide side.
The takeaway
Sermorelin is the hypothalamus's own signal, brief and injected, with an approval history in diagnosis and paediatrics. MK-677 is an oral ghrelin mimetic with a long adult trial record that is consistent on hormones and inconclusive on outcomes. They are complementary inputs to one system, not substitutes, and a comparison that ranks one above the other has usually confused a receptor with a result.
All products are intended for research use only. Not for human consumption. Must be 21 years of age or older to purchase.
References
1. Chapman, I. M., Bach, M. A., Van Cauter, E., et al. (1996). Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. Journal of Clinical Endocrinology and Metabolism, 81(12), 4249-4257.
2. Copinschi, G., Van Onderbergen, A., L'Hermite-Balériaux, M., et al. (1996). Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men. Journal of Clinical Endocrinology and Metabolism, 81(8), 2776-2782.
3. Fuh, V. L., & Bach, M. A. (1998). Growth hormone secretagogues: mechanism of action and use in aging. Growth Hormone and IGF Research, 8(1), 13-20.
4. Ghigo, E., Arvat, E., & Camanni, F. (1998). Orally active growth hormone secretagogues: state of the art and clinical perspectives. Annals of Medicine, 30(2), 159-168.
5. Svensson, J., Lönn, L., Jansson, J. O., et al. (1998). Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. Journal of Clinical Endocrinology and Metabolism, 83(2), 362-369.
6. Prakash, A., & Goa, K. L. (1999). Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs, 12(2), 139-157.
7. Nass, R., Pezzoli, S. S., Oliveri, M. C., et al. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Annals of Internal Medicine, 149(9), 601-611.
